Travere Therapeutics

Quarterly Financials

Values in thousands2025-09-302025-06-302025-03-312024-12-31
Revenue
$164,859
$114,449
$81,732
$74,787
Gross Profit
163,274
112,928
77,053
72,234
EBITDA
44,253
4,127
-25,528
-45,430
EBIT
28,465
-9,889
-38,330
-57,523
Net Income
25,706
-12,755
-41,226
-60,264
Net Change In Cash
164,859
114,449
81,732
74,787
Free Cash Flow
14,177
4,748
-53,978
-45,281
Cash
110,930
75,154
61,897
58,535
Basic Shares
102,618
88,946
88,356
83,105

Annual Financials

Values in thousands2024-12-312023-12-312022-12-312021-12-31
Revenue
$233,175
$145,238
$109,460
$131,836
Gross Profit
225,431
133,788
105,040
128,018
EBITDA
-265,773
-326,246
-299,422
-184,455
EBIT
-309,328
-364,776
-320,141
-197,201
Net Income
-321,545
-111,399
-278,482
-180,091
Net Change In Cash
233,175
145,238
109,460
131,836
Cost of Revenue
-101,271
79,268
Free Cash Flow
-338,687
-321,612
-214,657
-38,943
Cash
58,535
58,176
61,688
165,753
Basic Shares
78,889
74,267
63,758
59,832

Earnings Calls

QuarterEPS
2025-09-30
$0.59
2025-06-30
$0.13
2025-03-31
-$0.19
2024-12-31
-$0.47